Effects of canagliflozin on end-stage kidney disease and cardiovascular mortality in adults aged 50 years or older: an individual participant data meta-analysis of the CANVAS and CREDENCE trials
Authors' conclusion
Among these trial participants, canagliflozin produced a clinically meaningful, statistically significant 46.5% reduction in end-stage kidney disease. The effect on cardiovascular mortality was favourable but not statistically significant, likely reflecting limited power.
Study context
- Population
- Participants aged 50 years or older randomised in the CANVAS and CREDENCE trials; harmonised subject-level datasets from the Yale University Open Data Access Project3,955 CANVAS, 4,035 CREDENCE
- Comparison
- Canagliflozin vs placebo
- Outcome
- CV mortality and end-stage kidney disease
Methodological detailstwo-stage, age-tertile-stratified Cox proportional hazards models, restricted maximum likelihood pooling
- Two-stage
- Age-tertile-stratified Cox proportional hazards models
- Restricted maximum likelihood pooling
Pooled result
As reported in the abstract
- CV mortality events
- 309
- CV mortality, trial-level HR, CANVAS
- 0.874 (95% CI 0.623-1.226)
- CV mortality, trial-level HR, CREDENCE
- 0.814 (0.596-1.113)
- CV mortality, pooled HR
- 0.841 (0.669-1.058)
- End-stage kidney disease events
- 175
- End-stage kidney disease, HR, CANVAS
- 0.853 (0.250-2.916)
- End-stage kidney disease, HR, CREDENCE
- 0.518 (0.376-0.714; p < 0.001)
- End-stage kidney disease, pooled HR
- 0.535 (0.392-0.729)
Further pooled results
NNT at 3 years for end-stage kidney disease, CREDENCE
- NNT (Kaplan-Meier estimates)
- 27.5
Original publication
Effects of canagliflozin on end-stage kidney disease and cardiovascular mortality in adults aged 50 years or older: an individual participant data meta-analysis of the CANVAS and CREDENCE trials. Diabetes Res Clin Pract. Published 3 August 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →